Verrica Pharmaceuticals Inc.VRCANASDAQ
Loading
Year-over-year research & development expense growth
| Period | Value |
|---|---|
| Q4 2025 | 14.29% |
| Q3 2025 | 19.45% |
| Q2 2025 | -19.18% |
| Q1 2025 | 95.72% |
| Q4 2024 | -51.48% |
| Q3 2024 | -27.54% |
| Q2 2024 | -32.92% |
| Q1 2024 | -6.99% |
| Q4 2023 | -18.28% |
| Q3 2023 | 13.71% |
| Q2 2023 | 109.02% |
| Q1 2023 | -9.54% |
| Q4 2022 | 8.92% |
| Q3 2022 | -29.50% |
| Q2 2022 | 61.27% |
| Q1 2022 | -27.17% |
| Q4 2021 | -10.79% |
| Q3 2021 | 9.17% |
| Q2 2021 | -35.71% |
| Q1 2021 | 136.00% |
| Q4 2020 | -54.45% |
| Q3 2020 | 41.66% |
| Q2 2020 | -28.03% |
| Q1 2020 | 23.16% |
| Q4 2019 | 30.27% |
| Q3 2019 | -22.38% |
| Q2 2019 | -12.46% |
| Q1 2019 | -8.75% |
| Q4 2018 | 41.13% |
| Q3 2018 | -3.46% |
| Q2 2018 | 288.48% |
| Q1 2018 | -16.91% |
| Q4 2017 | -0.18% |
| Q3 2017 | 14.64% |
| Q2 2017 | 89.71% |
| Q1 2017 | 0.00% |